China: The Asian Dragon Lures Foreign Investors
This article was originally published in Start Up
Executive Summary
WuXi PharmaTech's spectacular public offering last summer piqued foreign investors' interest. Top tier VC firms are now investing in contract research organizations, manufacturing plays, and start-ups shifting business operations to China.
You may also be interested in...
Device Companies Look West, East, Anyplace But US
With clear regulatory approval paths in Europe and growing markets in Asia and other developing markets, device executives and investors see international markets as increasingly attractive alternatives for clinical validation, revenue, and regulatory approval.
Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model
In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding
Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model
In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding